{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:06:49Z","timestamp":1761523609046},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1053\/j.seminoncol.2009.02.005","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T08:26:25Z","timestamp":1240561585000},"page":"S6-S11","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S1","title":["Janus Kinase Mutations"],"prefix":"10.1053","volume":"36","author":[{"given":"Ross L.","family":"Levine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2009.02.005_bib1","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib2","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.leu.2404757","article-title":"Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes","volume":"21","author":"Tiu","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2007.06539.x","article-title":"Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia","volume":"137","author":"Keith","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib8","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib11","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib13","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2006-04-014712","article-title":"JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model","volume":"108","author":"Mercher","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib14","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1074\/jbc.M709302200","article-title":"Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2","volume":"283","author":"Dusa","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib16","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Frohling","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib17","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib18","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib19","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2006-04-016238","article-title":"Inside Blood: Does JAK2 1849G>T initiate polycythemia vera?","volume":"108","author":"Prchal","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib22","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib23","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","article-title":"Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders","volume":"111","author":"Hexner","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib24","doi-asserted-by":"crossref","first-page":"373s","DOI":"10.1200\/jco.2008.26.15_suppl.7004","article-title":"A phase I\/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera\/essential thrombocythemia myelofibrosis (Post-PV\/ET MF)","volume":"26","author":"Verstovsek","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib26","first-page":"170a","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"110","author":"Verstovsek","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20072182","article-title":"Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia","volume":"205","author":"Flex","year":"2008","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib28","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib29","first-page":"549","article-title":"Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells","volume":"60","author":"Joos","year":"2000","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib30","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood-2004-09-3701","article-title":"Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line","volume":"105","author":"Melzner","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib31","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib32","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI31871","article-title":"Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas","volume":"117","author":"Gao","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib33","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1210\/me.2007-0173","article-title":"Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a\/b pathways","volume":"21","author":"Neilson","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00280-008-0785-8","article-title":"CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells","volume":"63","author":"Duan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib35","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/carcin\/bgm042","article-title":"Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells","volume":"28","author":"Agarwal","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1053\/j.seminoncol.2009.02.005_bib36","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/mol.107.038117","article-title":"8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells","volume":"72","author":"Duan","year":"2007","journal-title":"Mol Pharmacol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T18:32:46Z","timestamp":1589740366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775409000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":36,"alternative-id":["S0093775409000335"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2009.02.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}